Effect of denosumab on the growing skeleton in osteogenesis imperfecta

J Clin Endocrinol Metab. 2014 Nov;99(11):3954-5. doi: 10.1210/jc.2014-3072. Epub 2014 Aug 22.

Authors

Heike Hoyer-Kuhn¹, Oliver Semler, Eckhard Schoenau

Affiliation

¹ Children's Hospital (H.H.-K., O.S., E.S.), University of Cologne, 50931 Cologne, Germany; and Cologne Center of Musculoskeletal Biomechanics (O.S., E.S.), 50931 Cologne, Germany.

PMID: 25148238
DOI: 10.1210/jc.2014-3072

No abstract available

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal, Humanized / pharmacology
Antibodies, Monoclonal, Humanized / therapeutic use*
Bone Density / drug effects*
Bone Density Conservation Agents / pharmacology
Bone Density Conservation Agents / therapeutic use
Bone Development / drug effects*
Bone and Bones / diagnostic imaging
Bone and Bones / drug effects*
Child
Denosumab
Diphosphonates / pharmacology
Diphosphonates / therapeutic use
Humans
Osteogenesis Imperfecta / diagnostic imaging
Osteogenesis Imperfecta / drug therapy*
Radiography
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Bone Density Conservation Agents
Diphosphonates
Denosumab